Search Medical Condition
Please enter condition
Please choose location from dropdown

Villajoyosa, Spain Clinical Trials

A listing of Villajoyosa, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

UCB Proof of Concept Study in Patients With Primary Sj gren's Syndrome

This is a Phase 2, multicenter, double-blind, placebo-controlled, 12-week proof-of-concept study to assess the efficacy, safety, and tolerability of UCB5857 in subjects with primary Sjögren's Syndrome (pSS). The primary objective of this study is to evaluate the efficacy on overall disease activity and safety of UCB5857 added to current treatment ...

Phase

0.0 miles

Learn More »

Retrospective Study to Determine the Incidence of Bone Fractures in HIV-infected Patients in Spain

Study to know the incidence of bone fractures in HIV patients, determine associate factors to bone fractures, the type of patients with fractures.

Phase N/A

0.0 miles

Learn More »

Firazyr Patient Registry Protocol (Icatibant Outcome Survey - IOS)

The Firazyr Patient Registry is a multicenter, prospective, observational study for patients treated with Firazyr in countries where it is currently approved. The entry of patients into the Firazyr Registry is at the discretion of the physician and the patient and is not a pre-requisite for prescribing Firazyr.

Phase N/A

0.0 miles

Learn More »

Hepatocellular Carcinoma in HIV-infected Patients

Observational study. All HIV-infected patients who have been diagnosed of hepatocellular carcinoma (HCC), following the American Association for the Study of Liver Diseases (AASLD) criteria, in the participant centers are included. Epidemiological, clinical and laboratory data are collected. The clinical and epidemiological characteristics of HCC cases will be analyzed. The ...

Phase N/A

0.0 miles

Learn More »

Mortality Reduction in Septic Shock by Plasma Adsorption

The study objective is to clarify whether the application of high doses CPFA (Coupled Plasma-Filtration Adsorption) in addition to the current clinical practice is able to reduce hospital mortality in septic shock patients in intensive care unit (ICU).

Phase N/A

0.0 miles

Learn More »

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

The purpose of this study is to demonstrate the impact of secukinumab on progression of structural damage in the spine, as measured by the mSASSS in patients with AS.

Phase

0.16 miles

Learn More »

Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

There is little information of Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 patients analyzed in the clinical trials. The rate of patients recruited into Treatment Chemotherapy as 1st Line in Advanced NSCLC clinical trials is less than 20 percent. This low rate makes the investigators think about the ...

Phase

5.76 miles

Learn More »

Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen

Erlotinib has demonstrated efficacy as a single agent in patients with NSCLC and the addition of erlotinib to chemotherapy has not achieved better results in the general population. However, several preclinical and phase I studies have shown that a sequential treatment of erlotinib and chemotherapy could avoid a possible negative ...

Phase

5.76 miles

Learn More »

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Oversight Authorities continued: Colombia- pending regulatory approval

Phase

5.76 miles

Learn More »

Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry

The registry will enroll 2 groups of patients. One group will include patients who are currently taking lupus medicines along with BENLYSTA (With BENLYSTA). The other group will include patients who are taking lupus medicines but do not take BENLYSTA (Without BENLYSTA). For every 3 participants enrolled in the registry, ...

Phase N/A

8.13 miles

Learn More »